Prostate Cancer Treatment Platform

Prostate Theranostic’s SMDC technology combines the targeting power of our proprietary urea-based PSMA ligand with carefully chosen therapeutic payloads designed to selectively kill cancer cells. If you have any questions or would like to discuss how our advancements impact health matters, please contact us. 

Our lead program links PSMA-targeting molecules to poly(ADP-ribose) polymerase (PARP) inhibitors, known to induce synthetic lethality in cancer cells with mutations in key DNA repair genes such as BRCA1 and BRCA2—these mutations are prevalent in a significant subset of aggressive prostate cancers.

Building on this foundation, we are expanding our platform to include additional therapeutic payloads such as androgen receptor inhibitors, taxanes, and next-generation DNA repair enzyme inhibitors, each designed to address different stages of prostate cancer progression.

Prostate Theranostic’s SMDC technology combines the targeting power of our proprietary urea-based PSMA ligand with carefully chosen therapeutic payloads designed to selectively kill cancer cells. If you have any questions or would like to discuss how our advancements impact health matters, please contact us. 

Our lead program links PSMA-targeting molecules to poly(ADP-ribose) polymerase (PARP) inhibitors, known to induce synthetic lethality in cancer cells with mutations in key DNA repair genes such as BRCA1 and BRCA2—these mutations are prevalent in a significant subset of aggressive prostate cancers.

Building on this foundation, we are expanding our platform to include additional therapeutic payloads such as androgen receptor inhibitors, taxanes, and next-generation DNA repair enzyme inhibitors, each designed to address different stages of prostate cancer progression.

Prostate Theranostic’s SMDC technology combines the targeting power of our proprietary urea-based PSMA ligand with carefully chosen therapeutic payloads designed to selectively kill cancer cells. If you have any questions or would like to discuss how our advancements impact health matters, please contact us. 

Our lead program links PSMA-targeting molecules to poly(ADP-ribose) polymerase (PARP) inhibitors, known to induce synthetic lethality in cancer cells with mutations in key DNA repair genes such as BRCA1 and BRCA2—these mutations are prevalent in a significant subset of aggressive prostate cancers.

Building on this foundation, we are expanding our platform to include additional therapeutic payloads such as androgen receptor inhibitors, taxanes, and next-generation DNA repair enzyme inhibitors, each designed to address different stages of prostate cancer progression.